Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MacroGenics stock in Canada | $32.19

Own MacroGenics shares in just a few minutes.

MacroGenics, Inc
NASDAQ: MGNX - USD
BIOTECHNOLOGY
$25.78
+$0.61 (+2.42%)

MacroGenics is a biotechnology business based in the US. MacroGenics stocks (MGNX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $27.17 – an increase of 8.86% over the previous week. MacroGenics employs 370 staff and has a trailing 12-month revenue of around $108.1 million.

How to buy MacroGenics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: MGNX in this case.
  5. Research MacroGenics stocks. The platform should provide the latest information available.
  6. Buy your MacroGenics stocks. It's that simple.

How has Coronavirus impacted MacroGenics's stock price?

Since the stock market crash in March caused by coronavirus, MacroGenics's stock price has had significant positive movement.

Its last market close was $32.19, which is 64.43% up on its pre-crash value of $11.45 and 696.78% up on the lowest point reached during the March crash when the stocks fell as low as $4.04.

If you had bought $1,000 worth of MacroGenics stocks at the start of February 2020, those stocks would have been worth $504.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $3,342.61.

MacroGenics stock price

Use our graph to track the performance of MGNX stocks over time.

MacroGenics stocks at a glance

Information last updated 2021-07-23.
Latest market close$32.19
52-week range$18.16 - $36.48
50-day moving average $24.9512
200-day moving average $26.7824
Wall St. target price$36.78
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.473

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy MacroGenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

MacroGenics price performance over time

Historical closes compared with the last close of $32.19

1 month (2021-06-25) 18.48%
3 months (2021-04-26) -7.90%

Is MacroGenics under- or over-valued?

Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MacroGenics's PEG ratio

MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

MacroGenics financials

Revenue TTM USD$108.1 million
Gross profit TTM USD$-88,318,000
Return on assets TTM -24.42%
Return on equity TTM -50.37%
Profit margin -126.1%
Book value $5.841
Market capitalisation USD$1.5 billion

TTM: trailing 12 months

How to short and sell MacroGenics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "MGNX.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.3 million MacroGenics stocks held short by investors – that's known as MacroGenics's "short interest". This figure is 4.5% up from 4.1 million last month.

There are a few different ways that this level of interest in shorting MacroGenics stocks can be evaluated.

MacroGenics's "short interest ratio" (SIR)

MacroGenics's "short interest ratio" (SIR) is the quantity of MacroGenics stocks currently shorted divided by the average quantity of MacroGenics stocks traded daily (recently around 1.2 million). MacroGenics's SIR currently stands at 3.56. In other words for every 100,000 MacroGenics stocks traded daily on the market, roughly 3560 stocks are currently held short.

However MacroGenics's short interest can also be evaluated against the total number of MacroGenics stocks, or, against the total number of tradable MacroGenics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MacroGenics's short interest could be expressed as 0.07% of the outstanding stocks (for every 100,000 MacroGenics stocks in existence, roughly 70 stocks are currently held short) or 0.0797% of the tradable stocks (for every 100,000 tradable MacroGenics stocks, roughly 80 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against MacroGenics.

Find out more about how you can short MacroGenics stock.

MacroGenics stock dividends

We're not expecting MacroGenics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

MacroGenics stock price volatility

Over the last 12 months, MacroGenics's stocks have ranged in value from as little as $18.16 up to $36.48. A popular way to gauge a stock's volatility is its "beta".

MGNX.US volatility(beta: 2.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 2.2454. This would suggest that MacroGenics's stocks are significantly more volatile than the average for this exchange and represent a higher risk.

MacroGenics overview

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Stocks similar to MacroGenics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site